CTLA4 and laryngotracheoesophageal cleft: Patients with active CC, but not LC, had significantly increased levels of the inhibitory checkpoint molecules CTLA-4 and PD-1 compared to both control groups as well as to CC-HR patients (Figures 4B,D).